Your browser doesn't support javascript.
loading
Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients.
Hassin, Ori; Nataraj, Nishanth Belugali; Shreberk-Shaked, Michal; Aylon, Yael; Yaeger, Rona; Fontemaggi, Giulia; Mukherjee, Saptaparna; Maddalena, Martino; Avioz, Adi; Iancu, Ortal; Mallel, Giuseppe; Gershoni, Anat; Grosheva, Inna; Feldmesser, Ester; Ben-Dor, Shifra; Golani, Ofra; Hendel, Ayal; Blandino, Giovanni; Kelsen, David; Yarden, Yosef; Oren, Moshe.
Afiliación
  • Hassin O; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Nataraj NB; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Shreberk-Shaked M; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Aylon Y; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Yaeger R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Fontemaggi G; Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Mukherjee S; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Maddalena M; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Avioz A; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Iancu O; The Institute for Advanced Materials and Nanotechnology, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
  • Mallel G; Pathology Department, Curesponse Ltd, Rehovot, Israel.
  • Gershoni A; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
  • Grosheva I; Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
  • Feldmesser E; Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Ben-Dor S; Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Golani O; Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.
  • Hendel A; The Institute for Advanced Materials and Nanotechnology, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel.
  • Blandino G; Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Kelsen D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yarden Y; Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
  • Oren M; Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. moshe.oren@weizmann.ac.il.
Nat Commun ; 13(1): 2800, 2022 05 19.
Article en En | MEDLINE | ID: mdl-35589715
ABSTRACT
The TP53 gene is mutated in approximately 60% of all colorectal cancer (CRC) cases. Over 20% of all TP53-mutated CRC tumors carry missense mutations at position R175 or R273. Here we report that CRC tumors harboring R273 mutations are more prone to progress to metastatic disease, with decreased survival, than those with R175 mutations. We identify a distinct transcriptional signature orchestrated by p53R273H, implicating activation of oncogenic signaling pathways and predicting worse outcome. These features are shared also with the hotspot mutants p53R248Q and p53R248W. p53R273H selectively promotes rapid CRC cell spreading, migration, invasion and metastasis. The transcriptional output of p53R273H is associated with preferential binding to regulatory elements of R273 signature genes. Thus, different TP53 missense mutations contribute differently to cancer progression. Elucidation of the differential impact of distinct TP53 mutations on disease features may make TP53 mutational information more actionable, holding potential for better precision-based medicine.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Colorrectales / Proteína p53 Supresora de Tumor Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Israel

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Colorrectales / Proteína p53 Supresora de Tumor Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2022 Tipo del documento: Article País de afiliación: Israel